History of interstitial lung disease.Xx_NEWLINE_xXNo known interstitial fibrosis or interstitial lung diseaseXx_NEWLINE_xXPatients must not have known interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicityXx_NEWLINE_xXNo patients with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicityXx_NEWLINE_xXHistory of interstitial lung diseaseXx_NEWLINE_xXHas a history of interstitial lung disease.Xx_NEWLINE_xXPatients with previous history or active interstitial lung disease or pulmonary fibrosis, or a history of other clinically significant lung diseasesXx_NEWLINE_xXSubjects with interstitial lung disease or interstitial pneumonitis that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicityXx_NEWLINE_xXHistory of interstitial lung disease or non-infectious pneumonia.Xx_NEWLINE_xXHistory of interstitial lung diseaseXx_NEWLINE_xXKnown history or confirmation of active pneumonia, pneumonitis, symptomatic interstitial lung disease, or definitive evidence of interstitial lung disease described on CT scan, MRI, or chest x-ray in asymptomatic patients; dyspnea at rest requiring current continuous oxygen therapy.Xx_NEWLINE_xXPatients with history of interstitial lung disease.Xx_NEWLINE_xXPatient has a known history of chronic interstitial lung diseaseXx_NEWLINE_xXSubject has a history of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies; any lung disease that may interfere with the detection or management of suspected drug-related pulmonary toxicityXx_NEWLINE_xXInterstitial lung disease with ongoing signs and symptoms at the time of informed consentXx_NEWLINE_xXHas a history of interstitial lung disease related to prior EGFR inhibitor therapy.Xx_NEWLINE_xXKnown pre-existing interstitial lung diseaseXx_NEWLINE_xXHas a history of interstitial lung diseaseXx_NEWLINE_xXParticipants with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity in the opinion of the treating investigatorXx_NEWLINE_xXHistory of interstitial lung disease.Xx_NEWLINE_xXHas a history of interstitial lung diseaseXx_NEWLINE_xXPast medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung diseaseXx_NEWLINE_xXHas interstitial lung disease that has required oral or intravenous glucocorticoids to assist with management.Xx_NEWLINE_xXSubjects with a history of interstitial lung diseaseXx_NEWLINE_xXSubjects with a history of interstitial lung disease (e.g., sarcoidosis) that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity; subjects with chronic obstructive pulmonary disease (COPD) whose disease is controlled at study entry are allowedXx_NEWLINE_xXHistory of extensive, disseminated, bilateral or presence of Grade 3 or 4 interstitial fibrosis or interstitial lung diseaseXx_NEWLINE_xXHas a history of interstitial lung diseaseXx_NEWLINE_xXSubjects with a history of interstitial lung diseaseXx_NEWLINE_xXPast medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.Xx_NEWLINE_xXHistory of interstitial lung diseaseXx_NEWLINE_xXPatients with evidence of interstitial lung disease (bilateral, diffuse, parenchymal lung disease)Xx_NEWLINE_xXClinically significant interstitial lung diseaseXx_NEWLINE_xXHistory or concurrent condition of interstitial lung disease of any grade or severely impaired pulmonary functionXx_NEWLINE_xXPatient has interstitial lung diseaseXx_NEWLINE_xXSymptomatic interstitial lung diseaseXx_NEWLINE_xXEvidence of interstitial lung diseaseXx_NEWLINE_xXKnown pre-existing interstitial lung diseaseXx_NEWLINE_xXPersistent proteinuria ? grade 3 Interstitial lung disease with ongoing signs and symptoms at the time of informed consentXx_NEWLINE_xXInterstitial lung disease with ongoing signs and symptoms at the time of informed consentXx_NEWLINE_xXKnown pre-existing interstitial lung diseaseXx_NEWLINE_xXInterstitial lung disease with ongoing signs and symptoms at the time of informed consentXx_NEWLINE_xXPre-existing interstitial lung diseaseXx_NEWLINE_xXPulmonary disease which, in the opinion of the investigator, may impair the patient's respiratory tolerance to moderate pulmonary fluid overload (e.g., interstitial lung disease, severe chronic obstructive pulmonary disease)Xx_NEWLINE_xXInterstitial lung disease that is symptomatic or which may interfere with the detection or management of suspected drug-related pulmonary toxicity.Xx_NEWLINE_xXHas a known history of interstitial lung diseaseXx_NEWLINE_xXHistory or any evidence of interstitial lung disease;Xx_NEWLINE_xXPast medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung diseaseXx_NEWLINE_xXParticipants must not have evidence of interstitial lung diseaseXx_NEWLINE_xXSubjects with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicityXx_NEWLINE_xXKnown pre-existing interstitial or inflammatory lung disease.Xx_NEWLINE_xXKnown moderate to severe chronic obstructive pulmonary disease, interstitial lung disease, or pulmonary fibrosisXx_NEWLINE_xXPast medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active interstitial lung diseaseXx_NEWLINE_xXHistory or concurrent condition of interstitial lung disease of any grade or severely impaired pulmonary functionXx_NEWLINE_xXKnown moderate to severe chronic obstructive pulmonary disease (COPD), interstitial lung disease, and pulmonary fibrosisXx_NEWLINE_xXEvidence of interstitial lung diseaseXx_NEWLINE_xXSubjects with a history of interstitial lung disease.Xx_NEWLINE_xXHas a history of interstitial lung diseaseXx_NEWLINE_xXPatient has a history of interstitial cystitisXx_NEWLINE_xXHas evidence of interstitial lung diseaseXx_NEWLINE_xXHas evidence of interstitial lung diseaseXx_NEWLINE_xXHas a history of interstitial lung disease.Xx_NEWLINE_xXHistory or active interstitial lung diseaseXx_NEWLINE_xXKnown interstitial lung diseaseXx_NEWLINE_xXSubjects with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicityXx_NEWLINE_xXInterstitial lung disease with ongoing signs and symptoms at the time of informed consentXx_NEWLINE_xXHistory of symptomatic idiopathic pulmonary fibrosis or interstitial lung diseaseXx_NEWLINE_xXPatient has a known history of chronic interstitial lung diseaseXx_NEWLINE_xXInterstitial lung disease with ongoing signs and symptoms at the time of informed consentXx_NEWLINE_xXGROUP 5:\r\n* Limited cutaneous scleroderma and SSc-related pulmonary disease with FVC < 80% or hemoglobin-adjusted DLCO < 70% of predicted\r\n* AND evidence of alveolitis/interstitial lung disease by high-resolution chest CT scan and/or by BAL (interstitial lung disease may be nonspecific interstitial pneumonia [NSIP] or usual interstitial pneumonia [UIP]; A bronchoalveolar lavage [BAL] should be done to confirm the findings of alveolitis only if the high resolution CT scan [HRCT] fails to show findings typically associated with systemic sclerosis changes [ground glass, NSIP, UIP, SSc related interstitial lung disease])\r\n* Alveolitis by BAL cell count will be defined based on a BAL cell differential count (> 3% neutrophils and/or > 2% eosinophils) from any lavaged lobeXx_NEWLINE_xXInterstitial lung diseaseXx_NEWLINE_xXKnown moderate to severe chronic obstructive pulmonary disease (COPD), interstitial lung disease, and pulmonary fibrosisXx_NEWLINE_xXInterstitial lung disease that is symptomatic or which may interfere with the detection or management of suspected drug-related pulmonary toxicityXx_NEWLINE_xXKnown pre-existing interstitial lung diseaseXx_NEWLINE_xXEvidence of interstitial lung diseaseXx_NEWLINE_xXInterstitial lung diseaseXx_NEWLINE_xXHas evidence of interstitial lung diseaseXx_NEWLINE_xXClinically significant interstitial pulmonary disease or known diagnosis of interstitial lung disease (ILD)Xx_NEWLINE_xXEvidence of interstitial lung diseaseXx_NEWLINE_xXHistory of, or evidence of clinically active, interstitial lung diseaseXx_NEWLINE_xXPatients have history of diagnosed interstitial lung diseaseXx_NEWLINE_xXHas evidence or a history of interstitial lung diseaseXx_NEWLINE_xXHas evidence of interstitial lung diseaseXx_NEWLINE_xXPatients with interstitial lung disease.Xx_NEWLINE_xXHas evidence of interstitial lung diseaseXx_NEWLINE_xXHistory or concurrent condition of interstitial lung disease of any grade or severely impaired pulmonary functionXx_NEWLINE_xXHistory or concurrent condition of interstitial lung disease and/or severely impaired lung function (as judged by the investigator)Xx_NEWLINE_xXHas evidence of interstitial lung diseaseXx_NEWLINE_xXSymptomatic lung diseaseXx_NEWLINE_xXInterstitial lung disease with ongoing signs and symptoms at the time of informed consentXx_NEWLINE_xXHistory of interstitial lung diseaseXx_NEWLINE_xXInterstitial lung disease that is symptomatic or may interfere with the detection or management of suspected treatment-related pulmonary toxicityXx_NEWLINE_xXPast medical history of interstitial lung disease, drug-induced interstitial disease, radiation pneumonitis which required steroid treatment or any evidence of clinically active interstitial lung diseaseXx_NEWLINE_xXHistory of interstitial lung disease, idiopathic pulmonary fibrosis, silicosis, sarcoidosis or connective tissue disorders (including rheumatoid arthritis and systemic lupus erythematosus)Xx_NEWLINE_xXHistory or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung functionXx_NEWLINE_xXHas evidence of interstitial lung diseaseXx_NEWLINE_xXPatients with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicityXx_NEWLINE_xXPatients with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicityXx_NEWLINE_xXPatients with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity Prior therapy:Xx_NEWLINE_xXSubjects with a history of symptomatic interstitial lung diseaseXx_NEWLINE_xXPatient has evidence of interstitial lung diseaseXx_NEWLINE_xXEvidence of interstitial lung diseaseXx_NEWLINE_xXNo interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lungXx_NEWLINE_xXPulmonary disease: severe chronic obstructive lung disease, or symptomatic restrictive lung diseaseXx_NEWLINE_xXPast medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung diseaseXx_NEWLINE_xXInterstitial pneumonia or interstitial fibrosis of the lung, which in the opinion of the site investigator could compromise the subject or the studyXx_NEWLINE_xXHistory of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis, or any evidence of interstitial lung disease on baseline chest CT scan\r\n* For the NSCLC expanded cohort only: scarring from previous radiation therapy or pneumonia allowedXx_NEWLINE_xXHistory or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function (as judged by the investigator).Xx_NEWLINE_xXEvidence of interstitial lung diseaseXx_NEWLINE_xXInterstitial lung disease or pulmonary fibrosisXx_NEWLINE_xXKnown history of active pneumonia, pneumonitis, symptomatic interstitial lung disease, or definitive evidence of interstitial lung disease described on CT scan, MRI, or chest x-ray in asymptomatic patients; dyspnea at rest requiring current continuous oxygen therapy.Xx_NEWLINE_xXHas a history of interstitial lung disease.Xx_NEWLINE_xXInterstitial lung diseaseXx_NEWLINE_xXSubjects with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity.Xx_NEWLINE_xXInterstitial lung disease that is symptomatic or may interfere with the detection or management of suspected treatment-related pulmonary toxicityXx_NEWLINE_xXKnown moderate to severe chronic obstructive pulmonary disease (COPD), interstitial lung disease, and pulmonary fibrosisXx_NEWLINE_xXActive or prior documented interstitial lung diseaseXx_NEWLINE_xXEvidence of interstitial lung diseaseXx_NEWLINE_xXEvidence of interstitial lung diseaseXx_NEWLINE_xXInterstitial lung disease with ongoing signs and symptoms at the time of informed consentXx_NEWLINE_xXInterstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicityXx_NEWLINE_xXHistory or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function (as judged by the investigator)Xx_NEWLINE_xXPatients with known and confirmed diagnosis of interstitial lung disease (IDL)Xx_NEWLINE_xXEvidence of interstitial lung diseaseXx_NEWLINE_xXKnown pre-existing interstitial lung diseaseXx_NEWLINE_xXPatients with clinically significant interstitial lung disease or history of cardiac diseaseXx_NEWLINE_xXPatients with known interstitial fibrosis or interstitial lung disease are not eligibleXx_NEWLINE_xXPatients with active interstitial lung diseaseXx_NEWLINE_xXPatients must not have any known clinically active interstitial lung diseaseXx_NEWLINE_xXPatients must not have interstitial lung disease that is symptomatic or disease that may interfere with the detection or management of suspected drug-related pulmonary toxicityXx_NEWLINE_xXPatients with known interstitial fibrosis or interstitial lung disease.Xx_NEWLINE_xXInterstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity.Xx_NEWLINE_xXEvidence of clinically active interstitial lung disease (ILD) and/or history of ILDXx_NEWLINE_xXSymptomatic intrinsic lung disease or lung involvementXx_NEWLINE_xXHistory of lung inflammation or disease.Xx_NEWLINE_xXSubject has a history of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies. Any lung disease that may interfere with the detection or management of suspected drug-related pulmonary toxicity.Xx_NEWLINE_xXClinically significant lung disease including known history or evidence of interstitial lung disease or chronic obstructive pulmonary disease (COPD) that requires oxygen therapyXx_NEWLINE_xXPast medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active interstitial lung diseaseXx_NEWLINE_xXHistory of interstitial lung diseaseXx_NEWLINE_xXHistory of interstitial lung diseaseXx_NEWLINE_xXHas a history of interstitial lung disease.Xx_NEWLINE_xXHistory of symptomatic or p previously established interstitial lung diseaseXx_NEWLINE_xXSymptomatic interstitial lung disease or definitive evidence of interstitial lung disease described on CT scan, MRI, or chest x-ray in asymptomatic patients; dyspnea at rest requiring current continuous oxygen.Xx_NEWLINE_xXSUB-PROTOCOL AIM A: Patients with a history of interstitial lung disease and/or pneumoniaXx_NEWLINE_xXInterstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung.Xx_NEWLINE_xXInterstitial lung disease with ongoing signs and symptoms at the time of informed consentXx_NEWLINE_xXInterstitial lung disease with ongoing signs and symptoms at the time of informed consent.Xx_NEWLINE_xXHistory of interstitial lung disease, idiopathic pulmonary fibrosis, silicosis or connective tissue disordersXx_NEWLINE_xXPast medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.Xx_NEWLINE_xXPatients must not have interstitial pneumonia or extensive symptomatic interstitial fibrosis of the lungXx_NEWLINE_xXKnown pre-existing interstitial lung disease.Xx_NEWLINE_xXHistory of or active interstitial lung diseaseXx_NEWLINE_xXSubjects with a history of interstitial lung diseaseXx_NEWLINE_xXHistory of interstitial lung diseaseXx_NEWLINE_xXAny evidence of clinically active interstitial lung disease (patients with chronic stable radiographic changes who are asymptomatic need not be excluded)Xx_NEWLINE_xXInterstitial lung disease with ongoing signs and symptoms at the time of informed consentXx_NEWLINE_xXPresence of interstitial lung disease, pulmonary fibrosis, or pulmonary hypersensitivity reactionXx_NEWLINE_xXEvidence of interstitial lung diseaseXx_NEWLINE_xXPatient has a history of interstitial cystitis.Xx_NEWLINE_xXSubjects with a history of interstitial lung diseaseXx_NEWLINE_xXHas evidence of interstitial lung diseaseXx_NEWLINE_xXInterstitial lung disease with ongoing signs and symptoms at the time of informed consentXx_NEWLINE_xXHistory or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function (as judged by the investigator)Xx_NEWLINE_xXInterstitial lung disease with ongoing signs and symptoms at the time of informed consentXx_NEWLINE_xXHistory of or current interstitial lung diseaseXx_NEWLINE_xXKnown pre-existing interstitial lung diseaseXx_NEWLINE_xXPatient with known pre-existing interstitial lung diseaseXx_NEWLINE_xXInterstitial lung disease with ongoing signs and symptoms at the time of informed consentXx_NEWLINE_xXInterstitial lung disease with ongoing signs and symptoms at the time of informed consentXx_NEWLINE_xXInterstitial lung disease with ongoing signs and symptoms at the time of informed consentXx_NEWLINE_xXSubjects with clinically significant interstitial lung disease, or obstructive disease without sufficient reserveXx_NEWLINE_xXHistory of interstitial lung diseaseXx_NEWLINE_xXInterstitial lung disease with ongoing signs and symptoms at the time of screeningXx_NEWLINE_xXOther clinically severe or uncontrolled systemic illness or any concurrent condition that in the view of the principal investigator could compromise the participant’s ability to tolerate vandetanib or could compromise study procedures or endpoints, including interstitial lung disease, drug-induced interstitial disease, radiation pneumonitis which required steroid treatment or any evidence of clinically active interstitial lung diseaseXx_NEWLINE_xXAny evidence of clinically active interstitial lung diseaseXx_NEWLINE_xXSymptomatic interstitial lung disease or definitive evidence of interstitial lung disease described on CT scan, MRI, or chest x-ray in asymptomatic patients; dyspnea at rest requiring current continuous oxygen therapy.Xx_NEWLINE_xXSubjects with a history of interstitial lung disease or lung disease that has required intubation in the past (i.e. such as asthma or chronic obstructive pulmonary disease [COPD]); patients requiring continuous supplemental oxygen are excludedXx_NEWLINE_xXPatients with evidence of interstitial lung diseaseXx_NEWLINE_xXKnown pre-existing interstitial lung diseaseXx_NEWLINE_xXPast medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.Xx_NEWLINE_xXInterstitial lung disease with ongoing signs and symptoms at the time of screening.Xx_NEWLINE_xXHistory or concurrent condition of interstitial lung diseaseXx_NEWLINE_xXHistory or concurrent condition of interstitial lung disease or severely impaired pulmonary functionXx_NEWLINE_xXPatients with any signs/symptoms of interstitial pneumoniaXx_NEWLINE_xXKnown pre-existing interstitial lung disease.Xx_NEWLINE_xXSubjects with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicityXx_NEWLINE_xXInterstitial lung disease with ongoing signs and symptoms at the time of informed consentXx_NEWLINE_xXInterstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lungXx_NEWLINE_xXHas a known history of interstitial lung diseaseXx_NEWLINE_xXHas a history of interstitial lung diseaseXx_NEWLINE_xXKnown history of, or any evidence of, interstitial lung diseaseXx_NEWLINE_xXAny evidence of clinically significant interstitial lung diseaseXx_NEWLINE_xXKnown interstitial lung diseaseXx_NEWLINE_xXPatients with clinically significant co-morbid conditions, including, but not limited to: hypotension, chronic interstitial lung disease, uncontrolled diabetesXx_NEWLINE_xXSubject has history of drug-induced interstitial lung disease (ILD) or any evidence of active ILD.Xx_NEWLINE_xXInterstitial lung disease with ongoing signs and symptoms at the time of study registration.Xx_NEWLINE_xXHistory of extensive disseminated interstitial fibrosis or any grade of interstitial lung disease.Xx_NEWLINE_xXKnown pre-existing interstitial lung diseaseXx_NEWLINE_xXHistory of interstitial lung disease.Xx_NEWLINE_xXSubject has history of drug-induced interstitial lung disease (ILD) or any evidence of active ILD.Xx_NEWLINE_xXSubjects with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicityXx_NEWLINE_xXSubject has history of drug-induced interstitial lung disease or any evidence of active interstitial lung disease.Xx_NEWLINE_xXHistory or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function (as judged by the investigator)Xx_NEWLINE_xXPatients with a prior diagnosis of interstitial lung disease or pulmonary fibrosisXx_NEWLINE_xXPre-existing or current interstitial lung diseaseXx_NEWLINE_xXInterstitial lung disease with ongoing signs and symptoms at the time of informed consentXx_NEWLINE_xXInterstitial lung disease with ongoing signs and symptoms at the time of informed consentXx_NEWLINE_xXHistory of interstitial lung disease (ILD)Xx_NEWLINE_xXKnown pre-existing Interstitial Lung Disease (ILD)Xx_NEWLINE_xXHas a history of interstitial lung disease.Xx_NEWLINE_xXInterstitial lung disease with ongoing signs and symptoms at the time of informed consent.Xx_NEWLINE_xXPatients with a history of interstitialXx_NEWLINE_xXNon-malignant interstitial lung disease;Xx_NEWLINE_xXNo prior history of VAT or open lung surgery (on the lung in which the procedure will be performed);Xx_NEWLINE_xXKnown preexisting interstitial lung disease, interstitial pulmonary fibrosis, or connective tissue disorder associated lung diseaseXx_NEWLINE_xXKnown pre-existing interstitial lung disease (ILD)Xx_NEWLINE_xXKnown moderate to severe chronic obstructive pulmonary disease (COPD), interstitial lung disease, pulmonary fibrosis, and pulmonary arterial hypotension.Xx_NEWLINE_xXHistory of interstitial lung disease (ILD)Xx_NEWLINE_xXHistory of interstitial lung disease (ILD)Xx_NEWLINE_xXRadiographically evident interstitial lung disease , concurrent infection, or a history of any of these conditionsXx_NEWLINE_xXInterstitial lung disease with ongoing signs and symptoms at the time of screeningXx_NEWLINE_xXKnown moderate to severe chronic obstructive pulmonary disease, interstitial lung disease, and pulmonary fibrosisXx_NEWLINE_xXInterstitial lung disease with ongoing signs and symptoms at the time of registrationXx_NEWLINE_xXHistory of interstitial lung diseaseXx_NEWLINE_xXEvidence of interstitial lung disease.Xx_NEWLINE_xXAny evidence of clinically active interstitial lung disease (patients with chronic,stable, radiographic changes who are asymptomatic need not be excluded).Xx_NEWLINE_xXKnown or suspected history of interstitial lung disease.Xx_NEWLINE_xXHistory of interstitial lung diseaseXx_NEWLINE_xXSubject has history of drug-induced interstitial lung disease (ILD) or any evidence of active ILD.Xx_NEWLINE_xXInterstitial lung disease with ongoing signs and symptoms at the time of informed consentXx_NEWLINE_xXHistory of interstitial lung diseaseXx_NEWLINE_xXHistory of interstitial cystitisXx_NEWLINE_xXPulmonary conditions such as chronic obstructive pulmonary disease, emphysema, interstitial lung disease, use of supplemental oxygenXx_NEWLINE_xXInterstitial lung disease with ongoing signs and symptoms at the time of informed consentXx_NEWLINE_xXAny serious intercurrent or psychiatric illness that could, in the investigator’s opinion, potentially interfere with the completion of treatment according to this protocol including but not limited to: \r\n* Uncontrolled diabetes mellitus (fasting plasma glucose > 130 mg/dL or 7.2 mmol/L)\r\n* Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease\r\n* Active infections \r\n* Gastrointestinal disease limiting the ability to swallow oral medications or absorb oral medications including refractory nausea and vomiting, chronic gastrointestinal diseases, inflammatory bowel disease; malabsorption syndromes\r\n* Patients with enteric stomata or significant bowel resection\r\n* Prior history of corneal ulceration\r\n* Patients with any evidence of severe or uncontrolled systemic liver disease including those with known hepatitis B and hepatitis C (excluding treated hepatitis C that has been cured)\r\n* Active bleeding diathesesXx_NEWLINE_xXSubjects with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity; NOTE: subjects must have baseline oxygen/saturation level requirements as aboveXx_NEWLINE_xXHas a serious cardiopulmonary medical condition (including cardiovascular disease, congestive heart failure [CHF], chronic obstructive pulmonary disease [COPD], restrictive lung disease, interstitial lung disease, asthma, acute or chronic bronchitis, cystic fibrosis, pneumonia, tuberculosis, pneumoconiosis, pulmonary hypertension, pulmonary embolism, pleural effusion, pneumothorax, obesity hyperventilation syndrome, neuromuscular lung disease)Xx_NEWLINE_xXPatients with a documented history of interstitial lung disease or pulmonary fibrosisXx_NEWLINE_xXHave heart disease, lung disease, or mental illnessXx_NEWLINE_xXActive interstitial lung disease; asthma requiring more than as needed bronchodilators for management; or other autoimmune lung diseaseXx_NEWLINE_xXUncontrolled intercurrent illness, including but not limited to interstitial lung disease.Xx_NEWLINE_xXHas interstitial lung diseaseXx_NEWLINE_xXHistory of interstitial lung disease (ILD).Xx_NEWLINE_xXSubjects with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicityXx_NEWLINE_xXHas history of interstitial lung disease.Xx_NEWLINE_xXHas active, or a history of, interstitial lung disease.Xx_NEWLINE_xXUncontrolled lung diseaseXx_NEWLINE_xXKnown interstitial lung disease.Xx_NEWLINE_xXHistory of interstitial lung disease (Parts D and E only).Xx_NEWLINE_xX